ZA200109345B - Method of enhancing insulin action. - Google Patents

Method of enhancing insulin action.

Info

Publication number
ZA200109345B
ZA200109345B ZA200109345A ZA200109345A ZA200109345B ZA 200109345 B ZA200109345 B ZA 200109345B ZA 200109345 A ZA200109345 A ZA 200109345A ZA 200109345 A ZA200109345 A ZA 200109345A ZA 200109345 B ZA200109345 B ZA 200109345B
Authority
ZA
South Africa
Prior art keywords
insulin action
enhancing insulin
enhancing
action
insulin
Prior art date
Application number
ZA200109345A
Other languages
English (en)
Inventor
Jerry L Nadler
Yoko Fujita Yamaguchi
Thomas W Balon
Original Assignee
Hope City
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hope City filed Critical Hope City
Publication of ZA200109345B publication Critical patent/ZA200109345B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200109345A 1999-04-30 2001-11-13 Method of enhancing insulin action. ZA200109345B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13200399P 1999-04-30 1999-04-30

Publications (1)

Publication Number Publication Date
ZA200109345B true ZA200109345B (en) 2003-04-30

Family

ID=22451988

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200109345A ZA200109345B (en) 1999-04-30 2001-11-13 Method of enhancing insulin action.

Country Status (10)

Country Link
US (1) US6316458B1 (zh)
EP (1) EP1183032A4 (zh)
JP (1) JP2002543135A (zh)
CN (1) CN1187051C (zh)
AU (1) AU4671000A (zh)
CA (1) CA2372948A1 (zh)
HK (1) HK1042852A1 (zh)
MX (1) MXPA01011077A (zh)
WO (1) WO2000066128A1 (zh)
ZA (1) ZA200109345B (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066101A2 (en) * 1999-04-30 2000-11-09 City Of Hope Method of inhibiting glycation product formation
US7393827B2 (en) 2004-12-30 2008-07-01 Diakine Therapeutics, Inc. Pharmaceutical compositions and methods for restoring β-cell mass and function
JP4863204B2 (ja) * 2005-06-15 2012-01-25 独立行政法人産業技術総合研究所 腎症関連疾患の診断方法及び診断キット
US8871764B2 (en) 2005-08-29 2014-10-28 University Of Virginia Patent Foundation Lisofylline analogs and methods for use
EP2325169B1 (en) * 2005-08-29 2015-10-07 University Of Virginia Patent Foundation Lisofylline analogues and their pharmeacuetical uses
WO2009097155A1 (en) * 2008-01-31 2009-08-06 Diakine Therapeutics, Inc. Compositions and methods for treating diabetes using lisofylline and islet neogenesis associated peptide
MX2010009300A (es) * 2008-02-29 2010-11-05 Concert Pharmaceuticals Inc Derivados de xantina substituidos.
US8263601B2 (en) 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
TWI466887B (zh) * 2009-08-26 2015-01-01 Concert Pharmaceuticals Inc 經取代的黃嘌呤衍生物
WO2011028820A1 (en) 2009-09-02 2011-03-10 Concert Pharmaceuticals, Inc. Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds
EP2473052A4 (en) * 2009-09-02 2013-03-20 Concert Pharmaceuticals Inc SUBSTITUTED XANTHINE DERIVATIVES
US9085788B2 (en) 2010-09-01 2015-07-21 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
US9074233B2 (en) 2010-09-01 2015-07-07 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
EP2696879A4 (en) * 2011-04-15 2014-11-26 Scimar Ltd USE OF S-ADENOSYLMETHIONINE, VITAMIN E AND VITAMIN C IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DYSFUNCTION
MX2014012384A (es) 2012-04-13 2014-11-26 Concert Pharmaceuticals Inc Derivados sustituidos de xantina.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648357A (en) 1992-03-04 1997-07-15 Cell Therapeutics, Inc. Enatiomerically pure hydroxylated xanthine compounds

Also Published As

Publication number Publication date
JP2002543135A (ja) 2002-12-17
AU4671000A (en) 2000-11-17
WO2000066128A1 (en) 2000-11-09
EP1183032A4 (en) 2002-08-21
CN1367696A (zh) 2002-09-04
HK1042852A1 (zh) 2002-08-30
US6316458B1 (en) 2001-11-13
EP1183032A1 (en) 2002-03-06
CA2372948A1 (en) 2000-11-09
CN1187051C (zh) 2005-02-02
MXPA01011077A (es) 2003-07-14

Similar Documents

Publication Publication Date Title
ZA200109439B (en) Method of polymerization.
ZA200108446B (en) Novel method of treatment.
ZA99104B (en) Method for administering ASPB28-human insulin.
GB2350852B (en) Well operating method
GB9918031D0 (en) Method
ZA200109345B (en) Method of enhancing insulin action.
ZA200204374B (en) Pre-filled syringe and method for making same.
GB9916757D0 (en) Method
GB0007871D0 (en) Method
GB9915625D0 (en) Method
ZA200210361B (en) Method of administering bishosphonates.
GB9919370D0 (en) Method
GB2355455B (en) Method
GB9920334D0 (en) Method
GB9924399D0 (en) Method
GB9915936D0 (en) Method
GB9911939D0 (en) Method
HK1062474A1 (en) Method of purifying b-secretase.
GB9906056D0 (en) Method
GB9907196D0 (en) Method
GB9908162D0 (en) Method
GB9909799D0 (en) Method
GB9909988D0 (en) Method
GB9911682D0 (en) Method
GB9911937D0 (en) Method